Adequan Canine  Returns to Luitpold Animal Health Product Portfolio - Business Solutions for Equine Practitioners | EquiManagement

Adequan Canine  Returns to Luitpold Animal Health Product Portfolio

Luitpold, manufacturer of Adequan Canine (polysulfated glycosaminoglycan), has returned marketing and distribution of this product to its own company.
Author:
Publish date:
Adequan Canine logo

Luitpold Animal Health, manufacturer of Adequan (polysulfated glycosaminoglycan) for horses, today announced that Adequan Canine, a product trusted for more than 20 years by veterinarians, rejoins its portfolio of leading FDA-approved joint health products.

“As the maker of Adequan Canine, Luitpold Pharmaceuticals has stood behind Adequan Canine from the start, ensuring quality, safety and efficacy standards are met,” said Joel Steckler, vice president of commercial operations for animal health. “Equine practitioners have confidently prescribed Adequan for nearly 30 years, so while you might not have known Luitpold by name, you have seen our commitment to making a difference with proven solutions.”

Supply and distribution should remain uninterrupted during this transition. Veterinarians can continue to purchase Adequan Canine through their authorized veterinary distributor and should direct questions regarding current or pending orders to their distributor. Customer and technical support will be handled by Luitpold Animal Health.

“Osteoarthritis is estimated to affect approximately 20 percent of dogs over one year of age (1), and can slowly take the joy out of life for a dog,” said McCloskey, DVM, pharmacovigilance veterinarian. “Protecting the joint cartilage in the early stages of the disease can make a real difference in the quality of a dog’s life. Adequan Canine has advanced joint health for thousands of dogs, helping them get back to being active by controlling the signs of canine arthritis.”

Adequan Canine is the only FDA-approved injectable, disease-modifying osteoarthritis drug (DMOAD) for dogs that inhibits enzymes which break down cartilage, so joint damage is reduced. (2) It is proven to help restore joint lubrication, relieve inflammation and renew the building blocks of healthy cartilage. (3)

“We look forward to working with veterinarians to continue delivering the potential benefits of Adequan Canine for dogs suffering from osteoarthritis,” said Steckler. “And for those veterinarians who have yet to discover its potential benefits, we hope you will take this opportunity to learn more. This change reflects the beginning of a new era for this long-standing brand, as well as for the animal health division of Luitpold.”

For customer support or to reach a Luitpold Animal Health sales representative, please call 800-458-0163, Monday-Friday, 8 a.m. to 6 p.m. ET or email cs@luitpold.com. For technical questions, call medical affairs at 888-354-4855, Monday-Friday, 9 a.m. to 5 p.m. ET. To report an adverse event, call 800-734-9236 or email pv@luitpold.com. To learn more about Adequan Canine visit adequancanine.com.

IMPORTANT SAFETY INFORMATION

Adequan Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. For additional safety information, please see full prescribing information.

About Luitpold Animal Health

For nearly 30 years, Luitpold Animal Health, a division of Luitpold Pharmaceuticals, Inc., has been committed to advancing animal health with proven FDA-approved products like Adequan. The company’s portfolio is anchored by the only FDA-approved equine polysulfated glycosaminoglycan for the intramuscular treatment of non-infectious degenerative joint disease of the carpal and hock joints, which has been relied on for nearly three decades by equine practitioners. As the manufacturer of Adequan Canine, the company recently returned marketing and distribution of the product to its portfolio, reflecting its position as a leader in joint health care for horses and dogs. Luitpold Pharmaceuticals, Inc., a Daiichi Sankyo Group Company, manufactures and distributes more than 100 human pharmaceutical products and devices, as well as innovative products for acute pain control and veterinary medicine use. The company continues to invest in its animal health portfolio as a strategic priority. For more information on Luitpold Animal Health, visit luitpoldanimalhealth.com or call 800- 458-0163.

References

1. Walton, M.B.; Cowderoy, E.; Lascelles, D.; Innes, J.F. (2013) Evaluation of Construct and Criterion Validity for the ‘Liverpool Osteoarthritis in Dogs’ (load) Clinical Metrology Instrument and Comparison to Two Other Instruments. PLoS ONE 8(3): e58125. doi:10.1371/journal.pone.0058125

2. Adequan Canine Prescribing Information, Rev. 1/18.

3. Adequan Canine (polysulfated glycosaminoglycan) NADA 141 -038 Freedom of Information Summary, 1997.